ConductScience.org, home

Paper2736308

A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.

Anger B and 5 others. Blut, 1989. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Papers, record 2736308. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2736308

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
PubMed
Journal
Blut
PubMed
Year
1989
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
0.69
iCite
Revised in PubMed
2020-12-22
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Anger BB
2Porzsolt FF
3Leichtle RR
4Heinze BB
5Bartram CC
6Heimpel HH

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HydroxyureaMajor topic
Interferon Type IMajor topic
Interferon-alphaMajor topic
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMajor topic
Antineoplastic Combined Chemotherapy Protocols
Drug Evaluation
Humans
Interferon alpha-2
L-Lactate Dehydrogenase
Leukocyte Count
Philadelphia Chromosome
Platelet Count
Recombinant Proteins

Source PubMed

Download CSV of topics

References10

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16956430Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia.Cancer1982https://conductscience.org/library/papers/6956430PubMed
23457264Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.N Engl J Med1986https://conductscience.org/library/papers/3457264PubMed
33471281Clinical investigation of human alpha interferon in chronic myelogenous leukemia.Blood1987https://conductscience.org/library/papers/3471281PubMed
43277680Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.Blut1988https://conductscience.org/library/papers/3277680PubMed
53516621[alpha 2-interferon: preliminary treatment results in chronic myeloid leukemia].Dtsch Med Wochenschr1986https://conductscience.org/library/papers/3516621PubMed
66952759Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia.Am J Clin Oncol1982https://conductscience.org/library/papers/6952759PubMed
73166389Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients.Blut1988https://conductscience.org/library/papers/3166389PubMed
82450402Therapy of chronic myelogenous leukemia: chemotherapy and interferons.Semin Hematol1988https://conductscience.org/library/papers/2450402PubMed
93115339Therapy of chronic myelogenous leukemia with recombinant interferon-gamma.Blood1987https://conductscience.org/library/papers/3115339PubMed
103165298Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.Blood1988https://conductscience.org/library/papers/3165298PubMed

Download CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
28624910Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?J Cancer Res Clin Oncol2017https://conductscience.org/library/papers/28624910PubMed
27057468Trial Watch-Immunostimulation with cytokines in cancer therapy.Oncoimmunology2016https://conductscience.org/library/papers/27057468PubMed
25083328Trial watch: Immunostimulatory cytokines in cancer therapy.Oncoimmunology2014https://conductscience.org/library/papers/25083328PubMed
19959212The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Gynecol Oncol2010https://conductscience.org/library/papers/19959212PubMed
12886239
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Leukemia2003https://conductscience.org/library/papers/12886239PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IFNA23440PubTator's text mininghttps://conductscience.org/library/genes/3440

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2736308

GET https://conductscience.org/api/papers/v1/2736308/authors